Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedApr 07, 2026
DataAggregated Company Financials
Companies147
  • 7D3.5%
  • 3M-2.2%
  • 1Y9.2%
  • YTD-2.3%

In the last week, the Healthcare industry is up 3.5%, with Swedish Orphan Biovitrum up 4.5%. This takes the industry's 12 month performance to a gain of 9.2%. Looking forward, earnings are forecast to grow by 24% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 07 Apr 2026SEK 570.3bSEK 228.9b-SEK 2,927,672,560.5330.9x-194.8x2.5x
Thu, 05 Mar 2026SEK 554.3bSEK 228.9b-SEK 2,461,655,449.0730.8x-225.2x2.4x
Sat, 31 Jan 2026SEK 582.1bSEK 229.0bSEK 3.4b37.5x171.2x2.5x
Mon, 29 Dec 2025SEK 583.9bSEK 230.4bSEK 3.6b43.6x160.2x2.5x
Wed, 26 Nov 2025SEK 597.4bSEK 230.9bSEK 3.3b44.7x183.8x2.6x
Fri, 24 Oct 2025SEK 608.1bSEK 228.4bSEK 3.3b46.5x185.7x2.7x
Sun, 21 Sep 2025SEK 618.8bSEK 227.4bSEK 6.6b46x93.8x2.7x
Tue, 19 Aug 2025SEK 614.3bSEK 226.7bSEK 6.6b46.7x92.8x2.7x
Thu, 17 Jul 2025SEK 635.8bSEK 227.0bSEK 6.1b44.8x103.6x2.8x
Sat, 14 Jun 2025SEK 603.9bSEK 226.4bSEK 5.8b40.1x103.6x2.7x
Mon, 12 May 2025SEK 600.8bSEK 224.1bSEK 5.2b34.5x114.9x2.7x
Wed, 09 Apr 2025SEK 533.2bSEK 221.4bSEK 5.4b31.5x97.9x2.4x
Fri, 07 Mar 2025SEK 558.8bSEK 206.1bSEK 4.7b35.5x118.5x2.7x
Sun, 02 Feb 2025SEK 602.2bSEK 204.1bSEK 1.5b43.6x394.3x2.9x
Tue, 31 Dec 2024SEK 581.6bSEK 202.6b-SEK 2,502,967,122.6439x-232.3x2.9x
Thu, 28 Nov 2024SEK 515.0bSEK 199.8b-SEK 2,815,717,640.2536.8x-182.9x2.6x
Sat, 26 Oct 2024SEK 597.4bSEK 201.8b-SEK 2,338,893,225.8939.7x-255.4x3x
Mon, 23 Sep 2024SEK 615.2bSEK 200.1b-SEK 2,816,505,402.9141.3x-218.4x3.1x
Wed, 21 Aug 2024SEK 597.0bSEK 199.9b-SEK 2,679,015,043.1740.3x-222.8x3x
Fri, 19 Jul 2024SEK 594.4bSEK 196.5b-SEK 3,096,010,871.4843.2x-192x3x
Sun, 16 Jun 2024SEK 555.8bSEK 195.5b-SEK 3,170,352,917.2135.3x-175.3x2.8x
Tue, 14 May 2024SEK 549.8bSEK 196.7b-SEK 2,686,959,272.8536x-204.6x2.8x
Thu, 11 Apr 2024SEK 522.6bSEK 192.7b-SEK 3,173,230,383.5945.3x-164.7x2.7x
Sat, 09 Mar 2024SEK 525.5bSEK 192.0b-SEK 3,685,987,655.6243.5x-142.6x2.7x
Mon, 05 Feb 2024SEK 537.3bSEK 193.6b-SEK 4,917,813,818.0050.1x-109.3x2.8x
Wed, 03 Jan 2024SEK 545.9bSEK 191.3b-SEK 964,552,472.0047.7x-566x2.9x
Fri, 01 Dec 2023SEK 498.7bSEK 190.0b-SEK 1,256,829,517.0051.1x-396.8x2.6x
Sun, 29 Oct 2023SEK 430.6bSEK 188.4b-SEK 1,511,030,224.0032x-284.9x2.3x
Tue, 26 Sep 2023SEK 454.4bSEK 185.3b-SEK 2,039,159,846.0036.3x-222.8x2.5x
Thu, 24 Aug 2023SEK 464.9bSEK 185.0b-SEK 1,810,255,799.0041.8x-256.8x2.5x
Sat, 22 Jul 2023SEK 478.1bSEK 182.9b-SEK 992,945,444.0041.5x-481.4x2.6x
Mon, 19 Jun 2023SEK 522.2bSEK 179.0b-SEK 774,500,144.0045x-674.2x2.9x
Wed, 17 May 2023SEK 522.2bSEK 177.0b-SEK 865,136,384.0042.7x-603.6x2.9x
Fri, 14 Apr 2023SEK 511.0bSEK 172.6b-SEK 1,424,920,130.0034.9x-358.6x3x
Price to Earnings Ratio

-358.6x


Total Market Cap: SEK 511.0bTotal Earnings: -SEK 1,424,920,130.00Total Revenue: SEK 172.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -163.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market2.65%
Healthcare3.47%
Healthtech5.20%
Biotech4.25%
Life Sciences4.19%
Pharma3.06%
Medical Equipment2.55%
Healthcare Services1.75%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 116x.
    • Analysts are expecting annual earnings growth of 20.2%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 400.804.5%
+SEK 5.9b		53.1%PE289.8x
SECT B SectraSEK 235.605.5%
+SEK 2.4b		0.08%PE84.5x
BONEX Bonesupport HoldingSEK 214.2014.2%
+SEK 1.8b		-27.7%PE100.6x
CAMX CamurusSEK 483.604.8%
+SEK 1.3b		-7.0%PE39.3x
IMP A SDB ImplanticaSEK 45.959.1%
+SEK 1.1b		78.8%PS575.1x

Latest News

SECT B
SEK 235.60
Sectra
7D
5.5%
1Y
0.08%

SECT B: Cloud Contracts And Rating Upgrades Will Shape Future Return Balance

Analysts have maintained the fair value estimate for Sectra at SEK 227.50. Recent upgrades and new price targets, which range from SEK 210 to SEK 250, support a slightly lower implied discount rate and marginally adjusted long-term growth and P/E assumptions.
BIOG B
SEK 116.90
BioGaia
7D
-0.3%
1Y
18.1%

BIOG B: Downgrade And Extra Dividend Will Set Up Future Multiple Re Rating

Analysts have trimmed their stance on BioGaia with a lower SEK price target, reflecting more cautious views on the shares following a downgrade from SEB Equities and only slight adjustments to assumptions such as the discount rate and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the trimmed price target and modest changes to the discount rate and future P/E as leaving room for upside if execution on growth initiatives tracks current expectations.
EKTA B
SEK 54.45
Elekta
7D
-2.5%
1Y
18.4%

EKTA B: Future Outlook Balances Mixed Ratings With Product Adoption Progress

Analysts lifted their fair value estimate for Elekta to SEK 58.27 from SEK 56.77, reflecting a higher assumed future P/E and recent Street research, where one firm raised its price target to SEK 60 while another turned more cautious on the shares. Analyst Commentary Bullish Takeaways Bullish analysts see the higher SEK 60 price target as better aligned with the updated fair value estimate, which now builds in a higher assumed P/E multiple.
CRNO B
SEK 6.49
Cereno Scientific
7D
-12.7%
1Y
11.5%
BONEX
SEK 214.20
Bonesupport Holding
7D
14.2%
1Y
-27.7%
SOBI
SEK 400.80
Swedish Orphan Biovitrum
7D
4.5%
1Y
53.1%
CAMX
SEK 483.60
Camurus
7D
4.8%
1Y
-7.0%

CAMX: FDA Review Of Resubmitted NDA Will Drive Future Upside

Analysts have trimmed their 12 month price target for Camurus from SEK 660 to SEK 610, citing updated assumptions that include revised revenue growth, profit margin and future P/E expectations. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, framed against internal 2025 expectations (Key Developments).
GETI B
SEK 191.20
Getinge
7D
2.1%
1Y
5.2%

Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next

Mar 29
Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
BIOA B
SEK 327.40
BioArctic
7D
3.9%
1Y
98.8%
ALIF B
SEK 142.00
AddLife
7D
4.6%
1Y
1.1%

ALIF B: Higher Margin Outlook And Dividend Policy Will Support Future Upside

Analysts have trimmed their price target for AddLife from SEK191.50 to SEK187.50, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E levels. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.5000 per share, with an ex date on May 7, 2026, a record date on May 8, 2026, and a payment date on May 13, 2026 (Key Developments).
XSPRAY
SEK 28.00
Xspray Pharma
7D
-2.4%
1Y
3.9%
FLERIE
SEK 29.70
Flerie
7D
-17.6%
1Y
-26.6%
ORT B
SEK 7.98
Ortoma
7D
-15.6%
1Y
-2.2%
CANTA
SEK 4.03
Cantargia
7D
-2.1%
1Y
222.9%
IMP A SDB
SEK 45.95
Implantica
7D
9.1%
1Y
78.8%
CINPHA
SEK 16.30
Cinclus Pharma Holding
7D
-4.5%
1Y
52.6%